# Treatment of Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells (MSV)

> **NCT01860417** · PHASE1,PHASE2 · COMPLETED · sponsor: **Red de Terapia Celular** · enrollment: 24 (actual)

## Conditions studied

- Degenerative Disc Disease
- Intervertebral Disc Disease
- Low Back Pain

## Interventions

- **BIOLOGICAL:** Allogenic Mesenchymal Stromal Cells
- **DRUG:** Mepivacaine

## Key facts

- **NCT ID:** NCT01860417
- **Lead sponsor:** Red de Terapia Celular
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-21
- **Primary completion:** 2015-12-15
- **Final completion:** 2015-12-15
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-04-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01860417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01860417, "Treatment of Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells (MSV)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01860417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*